Skip to main content

A PHASE IIIb MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS

Open
  • Protocol code: WA40404
  • EudraCT code: 2018-001511-73
  • Research group: Clinical Neuroimmunology
  • Service: Neuroimmunology
  • Principal investigator:  Montalban Gairín, Xavier
  • Phase: Fase III
  • Status: Recruiting volunteers